This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The 5 Dumbest Things on Wall Street This Week: Sept. 28

4. Questcor Crumbles

Here's one for your 'Never catch a falling knife' or 'Trust a stupid analyst' files.

On Sept. 19, shares of Questcor Pharmaceuticals (QCOR) lost nearly half their value, falling to $26 from $50 after insurer Aetna (AET) said it would limit coverage of the company's top-selling multiple sclerosis and infant seizure drug Acthar. The selloff was the stock's biggest one-day drop since November 1992.

For its part, the drug maker said it didn't expect a "material impact" from the change, notwithstanding the stock's shellacking. And for their part, the analysts covering Questcor took the company at its word and told their followers to scoop up the beaten-down stock with both fists.

Did they counsel 'safety first' in the wake of such a massive selloff? Were they worried at all that other insurers would follow suit, or fear that something deeper may be afoot? Did they extract any measure of restraint from the short sellers that comprise roughly 35% of the company's outstanding shares?

No, no, no and no. The ensuing research notes last Thursday from Oppenheimer, Piper Jaffray, ThinkEquity and Leerink Swann all screamed buy, buy, buy and buy. The selloff had created a once in a lifetime bargain they opined. The coast, in their learned view, was clear, and the worst, in their experience, was over.

Alas, that was not the case at all. And investors who threw caution to the wind and rushed into the stock based on these analysts supposedly sage advice quickly discovered that the coast was in fact craggy and the worst was indeed yet to come.

On Sept. 24, Questcor announced it was under investigation by regulators over its promotional practices, sending its shares down another 37% to $19. On the heels of that news, Questcor refused to name the agency undertaking the inquiry and said it would not be available for further comment.

Guess who subsequently downgraded Questcor due to this "uncertainty"? Guess who said the "investigation overhang" wasn't going away anytime soon? Guess who told investors to "move to the sidelines"? Guess who sliced his rating as a result of "reimbursement risk"?

Yes, yes, yes and yes indeed. Our friends, the analysts, had all abandoned Questcor's quest, a mere two trading days after pounding the table with bullish calls.

To which we say: Oh no, no, no and not again!

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
QCOR $93.60 1.65%
BTH $7.60 0.00%
INTC $32.00 0.00%
TSLA $185.00 0.00%
AAPL $123.25 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs